Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jeremy D Waight"'
Autor:
Agathe Dubuisson, Jean‐Eudes Fahrner, Anne‐Gaëlle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Séverine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camélia Radulescu, Sophie Ferlicot, David J Figueroa, Sapna Yadavilli, Jeremy D Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, François Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice André, Cédric Lebacle, Hervé Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean‐Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurélien Marabelle, Mélodie Bonvalet, Laurence Zitvogel
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an
Externí odkaz:
https://doaj.org/article/67054ca5ed634665a330aa95af51b5fb
Autor:
Randi B Gombos, Ana Gonzalez, Mariana Manrique, Dhan Chand, David Savitsky, Benjamin Morin, Ekaterina Breous-Nystrom, Christopher Dupont, Rebecca A Ward, Cornelia Mundt, Benjamin Duckless, Hao Tang, Mark A Findeis, Andrea Schuster, Jeremy D Waight, Dennis Underwood, Christopher Clarke, Gerd Ritter, Taha Merghoub, David Schaer, Jedd D Wolchok, Marc van Dijk, Jennifer S Buell, Jean-Marie Cuillerot, Robert Stein, Elise E Drouin, Nicholas S Wilson
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0191926 (2018)
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety o
Externí odkaz:
https://doaj.org/article/a2c5e638342c4ecea28b08aa00701413
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e27690 (2011)
Myeloid-derived suppressor cells (MDSC) are induced under diverse pathologic conditions, including neoplasia, and suppress innate and adaptive immunity. While the mechanisms by which MDSC mediate immunosuppression are well-characterized, details on h
Externí odkaz:
https://doaj.org/article/c2a6de5b578045d2aa1a425aecd172d6
Autor:
Hasan Alsaid, Shih-Hsun Cheng, Meixia Bi, Fang Xie, Mary Rambo, Tinamarie Skedzielewski, Bao Hoang, Sunish Mohanan, Debra Comroe, Andrew Gehman, Chih-Yang Hsu, Kamyar Farhangi, Hoang Tran, Valeriia Sherina, Minh Doan, M. Reid Groseclose, Christopher B. Hopson, Sara Brett, Ian A. Wilson, Andrew Nicholls, Marc Ballas, Jeremy D. Waight, Beat M. Jucker
Publikováno v:
Molecular Imaging and Biology. 25:528-540
Purpose The presence and functional competence of intratumoral CD8+ T cells is often a barometer for successful immunotherapeutic responses in cancer. Despite this understanding and the extensive number of clinical-stage immunotherapies focused on po
Autor:
Lucero, Valenzuela-Vázquez, Juan Carlos, Nuñez-Enriquez, Jacqueline, Sánchez-Herrera, Aurora, Medina-Sanson, María Luisa, Pérez-Saldivar, Elva, Jiménez-Hernández, Jorge Alfonso, Martiín-Trejo, María de Los Ángeles, Del Campo-Martínez, Janet, Flores-Lujano, Raquel, Amador-Sánchez, Félix Gustavo, Mora-Ríos, José Gabriel, Peñaloza-González, David Aldebarán, Duarte-Rodríguez, José Refugio, Torres-Nava, Rosa Martha, Espinosa-Elizondo, Beatriz, Cortés-Herrera, Luz Victoria, Flores-Villegas, Laura Elizabeth, Merino-Pasaye, Carolina, Almeida-Hernández, Rosario, Ramírez-Colorado, Karina Anastacia, Solís-Labastida, Francisco, Medrano-López, Jessica Arleet, Pérez-Gómez, Martha Margarita, Velázquez-Aviña, Annel, Martínez-Ríos, Antonio, Aguilar-De Los Santos, Jessica Denisse, Santillán-Juárez, Alma, Gurrola-Silva, Alejandra Jimena, García-Velázquez, Minerva, Mata-Rocha, Gabriela Alicia, Hernández-Echáurregui, Omar Alejandro, Sepúlveda-Robles, Haydeé, Rosas-Vargas, Ismael, Mancilla-Herrera, Silvia, Jimenez-Morales, Alfredo, Hidalgo-Miranda, Ivan, Martinez-Duncker, Jeremy D, Waight, Kenneth W, Hance, Kevin P, Madauss, Juan Manuel, Mejía-Aranguré, Mario Ernesto, Cruz-Munoz
Publikováno v:
Frontiers in Oncology. 12
NK cells have unique attributes to react towards cells undergoing malignant transformation or viral infection. This reactivity is regulated by activating or inhibitory germline encoded receptors. An impaired NK cell function may result from an aberra
Publikováno v:
Frontiers in Immunology. 13
In recent years, a set of immune receptors that interact with members of the nectin/nectin-like (necl) family has garnered significant attention as possible points of manipulation in cancer. Central to this axis, CD226, TIGIT, and CD96 represent liga
Autor:
Kenneth W. Hance, Paul Bojczuk, Christine Donahue, Michael Conner, James F. Smothers, Iris Roth, Jeremy D. Waight, Katie Vowell, Florence Perrin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundIn recent years, a regulatory network involving nectin/nectin-like immune receptors has emerged as a potential point of manipulation for cancer immunotherapy. Central to this axis, CD226 (DNAM-1) is a T and NK cell co-stimulatory receptor t
Autor:
Bulent Arman Aksoy, Thomas Horn, Lukasz Swiech, Jeremy D. Waight, David Savitsky, Dhan Chand, Simarjot Pabla, Benjamin Duckless, Jennifer Buell, Tenzing Khendu, Andrew Basinski, Cailin Joyce
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Anti-PD-1 therapies have achieved durable clinical responses in a wide range of malignancies, but responses are limited to a small subset of patients. Expression of PD-L1 on tumor cells by immunohistochemistry (IHC) has been applied as a c
Autor:
Marilyn Marques, Nicholas S. Wilson, Sylvia Dietrich, Jennifer Buell, Jeremy D. Waight, Rebecca Ward, Elena Paltrinieri, Dhan Chand, David Savitsky, Mark Bushell, Priyadarshini Iyer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an important negative regulator of the immune response to cancer that contributes to resistance/relapse to anti-PD-1 therapy.1 In clinical trials, anti-human (h) TIGIT antibodies ha
Autor:
Chris Hopson, Jeremy D. Waight, Axel Hoos, Marc S. Ballas, Meixia Bi, Sapna Yadavilli, Kenneth W. Hance
Publikováno v:
Cancer Research. 81:1849-1849
In recent years, antibody-based immunotherapies targeting immune checkpoint proteins cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have revolutionized the treatment of cancer. Despite durable clinical responses in